Ascendis Pharma A/S (ASND): Price and Financial Metrics


Ascendis Pharma A/S (ASND): $114.15

-1.95 (-1.68%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ASND to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ASND POWR Grades

  • ASND scores best on the Value dimension, with a Value rank ahead of 51.12% of US stocks.
  • The strongest trend for ASND is in Stability, which has been heading down over the past 177 days.
  • ASND's current lowest rank is in the Quality metric (where it is better than 14.38% of US stocks).

ASND Stock Summary

  • With a one year PEG ratio of 2,136.67, ASCENDIS PHARMA A is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 98.53% of US stocks.
  • With a price/sales ratio of 206.44, ASCENDIS PHARMA A has a higher such ratio than 98.25% of stocks in our set.
  • As for revenue growth, note that ASND's revenue has grown 723.59% over the past 12 months; that beats the revenue growth of 98.46% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to ASCENDIS PHARMA A, a group of peers worth examining would be VLN, TFFP, SPCE, MRNS, and FUSN.
  • Visit ASND's SEC page to see the company's official filings. To visit the company's web site, go to www.ascendispharma.com.

ASND Stock Price Chart Interactive Chart >

Price chart for ASND

ASND Price/Volume Stats

Current price $114.15 52-week high $134.52
Prev. close $116.10 52-week low $61.58
Day low $113.80 Volume 193,543
Day high $116.53 Avg. volume 280,591
50-day MA $119.70 Dividend yield N/A
200-day MA $103.18 Market Cap 6.51B

Ascendis Pharma A/S (ASND) Company Bio


Ascendis Pharma A/S is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained release technologies, to develop a pipeline of best-in-class therapeutics that address significant unmet medical needs. The company was founded in 2006 and is based in Hellerup, Denmark.


ASND Latest News Stream


Event/Time News Detail
Loading, please wait...

ASND Latest Social Stream


Loading social stream, please wait...

View Full ASND Social Stream

Latest ASND News From Around the Web

Below are the latest news stories about ASCENDIS PHARMA A that investors may wish to consider to help them evaluate ASND as an investment opportunity.

What Makes Ascendis Pharma A/S (ASND) an Attractive Investment Choice?

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund increased by 9.08% (Institutional Shares) compared to an 11.54% gain for the Russell 3000 Health Care Index and a 7.56% gain for the S&P […]

Yahoo | January 31, 2023

Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Morgan Healthcare Conference

– On track to fulfill all elements of Vision 3x3 to build a sustainable, profitable, leading biopharma company COPENHAGEN, Denmark, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided an update on its Vision 3x3 strategic roadmap and planned 2023 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present the update tomorrow, January 9, at the 41st Annual J.P. Morgan Healthcare Conference. “As we approach anticipated launch of our second endocr

Yahoo | January 8, 2023

Ascendis Pharma's (NASDAQ:ASND) growing losses don't faze investors as the stock climbs 3.8% this past week

When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...

Yahoo | January 8, 2023

Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma’s TransCon™ PTH for Eligible U.S. Adult Patients with Hypoparathyroidism

- The Expanded Access Program (EAP) allows physicians to request access to TransCon PTH, the company’s investigational parathyroid hormone replacement therapy, for eligible patients in the United States - TransCon PTH is under Priority Review by the FDA, with a target PDUFA date of April 30, 2023 COPENHAGEN, Denmark, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the online portal is now open for physicians wanting to request access to TransCon PTH (pal

Yahoo | January 4, 2023

Ascendis Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the Company is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference. Details: Event41st Annual J.P. Morgan Healthcare ConferenceLocationSan Francisco, CADateMonday, January 9, 2023Time12:00-12:40 p.m. Eastern Time / 9:00-9:40 a.m. Pacific Time A live webcast of the event will be available via the Investors & News section of the Ascendis Pharma website at https://inv

Yahoo | January 3, 2023

Read More 'ASND' Stories Here

ASND Price Returns

1-mo -9.96%
3-mo -7.88%
6-mo 19.98%
1-year -6.29%
3-year -20.45%
5-year 122.43%
YTD -6.53%
2022 -9.22%
2021 -19.34%
2020 19.88%
2019 122.06%
2018 56.39%

Continue Researching ASND

Want to see what other sources are saying about Ascendis Pharma A's financials and stock price? Try the links below:

Ascendis Pharma A (ASND) Stock Price | Nasdaq
Ascendis Pharma A (ASND) Stock Quote, History and News - Yahoo Finance
Ascendis Pharma A (ASND) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8465 seconds.